|
1
|
Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study.
|
Diabetes Care
|
2003
|
1.40
|
|
2
|
In vivo roles of factor XII.
|
Blood
|
2012
|
1.37
|
|
3
|
Platelet dysfunction in patients with severe traumatic brain injury.
|
J Neurotrauma
|
2007
|
1.15
|
|
4
|
Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers.
|
J Neurotrauma
|
2007
|
0.95
|
|
5
|
Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin.
|
Arterioscler Thromb Vasc Biol
|
2006
|
0.89
|
|
6
|
Marked increase of fibrin gel permeability with very low dose ASA treatment.
|
Thromb Res
|
2005
|
0.88
|
|
7
|
A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
|
Thromb Haemost
|
2007
|
0.84
|
|
8
|
Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations?
|
Clin Chem Lab Med
|
2008
|
0.84
|
|
9
|
Changes in von Willebrand factor and ADAMTS13 during IVF.
|
Blood Coagul Fibrinolysis
|
2011
|
0.84
|
|
10
|
Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers.
|
Thromb Res
|
2007
|
0.83
|
|
11
|
Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light.
|
Transfusion
|
2003
|
0.83
|
|
12
|
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
|
Blood Coagul Fibrinolysis
|
2007
|
0.83
|
|
13
|
Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials.
|
Blood Coagul Fibrinolysis
|
2005
|
0.82
|
|
14
|
In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
|
J Thromb Thrombolysis
|
2013
|
0.82
|
|
15
|
The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
|
Thromb Haemost
|
2010
|
0.81
|
|
16
|
Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis.
|
J Cardiovasc Pharmacol
|
2009
|
0.81
|
|
17
|
Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
|
Blood Coagul Fibrinolysis
|
2003
|
0.80
|
|
18
|
Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction.
|
Thromb Haemost
|
2012
|
0.80
|
|
19
|
On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin.
|
Blood Coagul Fibrinolysis
|
2003
|
0.79
|
|
20
|
Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study.
|
Biochem Biophys Res Commun
|
2012
|
0.79
|
|
21
|
Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease.
|
Blood Coagul Fibrinolysis
|
2016
|
0.79
|
|
22
|
Clotting onset time may be a predictor of outcome in human brain injury: a pilot study.
|
J Neurosurg Anesthesiol
|
2003
|
0.78
|
|
23
|
Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?
|
Thromb Res
|
2011
|
0.78
|
|
24
|
Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma.
|
Blood Coagul Fibrinolysis
|
2005
|
0.77
|
|
25
|
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus.
|
Blood Coagul Fibrinolysis
|
2009
|
0.76
|
|
26
|
Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation.
|
Br J Haematol
|
2003
|
0.76
|
|
27
|
Are results of fibrinogen measurements transferable?
|
Clin Chem Lab Med
|
2003
|
0.76
|
|
28
|
Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
|
Thromb Haemost
|
2016
|
0.75
|
|
29
|
Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women.
|
Fertil Steril
|
2002
|
0.75
|
|
30
|
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
|
Thromb Res
|
2002
|
0.75
|
|
31
|
Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
|
Thromb Haemost
|
2014
|
0.75
|
|
32
|
A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
|
Br J Haematol
|
2013
|
0.75
|
|
33
|
Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxin.
|
Thromb Res
|
2003
|
0.75
|